Prediction of the phosphorylation signal response of receptor-type tyrosine kinase (RTK) inhibitors using miRNA as a biomarker.
| Project/Area Number |
15K08083
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Meiji Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | miRNA / RTK阻害薬 / キナーゼシグナル / バイオマーカー / リン酸化シグナル / 分子標的薬 / キナーゼ阻害剤 |
|---|
| Outline of Final Research Achievements |
This study was performed that predicting the effect of receptor type tyrosine kinase (RTK) inhibitors with miRNA as a biomarker. We found that miR-205 was overexpressed in Gefinitib-resistant lung cancer cell lines with MET amplification. The reporter assay system was developed for kinase signal prediction in gefitinib resistant lung cancer cell lines. This screening system revealed that miR-205 expression was down regulated by pI3K Akt inhibitors. In conclusion, clarified the possibility of phosphorylation signal as a regulator of the miRNA expression.
|
Report
(4 results)
Research Products
(8 results)
